Targeted therapy is lagging behind in esophageal adenocarcinoma (EAC). To guide the development of new treatment strategies, we provide an overview of the prognostic biomarkers in resectable EAC treated with curative intent. The Medline, Cochrane and EMBASE databases were systematically searched, focusing on overall survival (OS). The quality of the studies was assessed using a scoring system ranging from 0–7 points based on modified REMARK criteria. To evaluate all identified prognostic biomarkers, the hallmarks of cancer were adapted to fit all biomarkers based on their biological function in EAC, resulting in the features angiogenesis, cell adhesion and extra-cellular matrix remodeling, cell cycle, immune, invasion and metastasis, proliferation, and self-renewal. Pooled hazard ratios (HR) and 95% confidence intervals (CI) were derived by random effects meta-analyses performed on each hallmarks of cancer feature. Of the 3298 unique articles identified, 84 were included, with a mean quality of 5.9 points (range 3.5–7). The hallmarks of cancer feature ‘immune’ was most significantly associated with worse OS (HR 1.88, (95%CI 1.20–2.93)). Of the 82 unique prognostic biomarkers identified, meta-analyses showed prominent biomarkers, including COX-2, PAK-1, p14ARF, PD-L1, MET, LC3B, IGFBP7 and LGR5, associated to each hallmark of cancer.

Additional Metadata
Persistent URL dx.doi.org/10.1038/s41598-018-31548-6, hdl.handle.net/1765/110166
Journal Scientific Reports
Citation
Creemers, A. (Aafke), Ebbing, E.A. (Eva A.), Pelgrim, T.C. (Thomas C.), Lagarde, S.M, van Etten-Jamaludin, F.S. (Faridi S.), van Berge Henegouwen, M.I, … van Laarhoven, H.W.M. (2018). A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas. Scientific Reports, 8(1). doi:10.1038/s41598-018-31548-6